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ABSTRACT
Objective: To compare the prognostic accuracy of various acute stroke prognostic scales using
a large, independent, clinical trials dataset.
Methods: We directly compared 8 stroke prognostic scales, chosen based on focused literature
review (Acute Stroke Registry and Analysis of Lausanne [ASTRAL]; iSCORE; iSCORE-revised; pre-
admission comorbidities, level of consciousness, age, and neurologic deficit [PLAN]; stroke subtype,
Oxfordshire Community Stroke Project, age, and prestroke modified Rankin Scale [mRS] [SOAR];
modified SOAR; Stroke Prognosis Instrument 2 [SPI2]; and Totaled Health Risks in Vascular Events
[THRIVE]) using individual patient-level data from a clinical trials archive (Virtual International Stroke
Trials Archive [VISTA]). We calculated area under receiver operating characteristic curves (AUROC)
for each scale against 90-day outcomes ofmRS (dichotomized atmRS.2), Barthel Index (.85), and
mortality. We performed 2 complementary analyses: the first limited to patients with complete data
for all components of all scales (simultaneous) and the second using asmany patients as possible for
each individual scale (separate). We compared AUROCs and performed sensitivity analyses
substituting extreme outcome values for missing data.
Results: In total, 10,777 patients contributed to the analyses. Our simultaneous analyses sug-
gested that ASTRAL had greatest prognostic accuracy for mRS, AUROC 0.78 (95% confidence
interval [CI] 0.75–0.82), and SPI2 had poorest AUROC, 0.61 (95% CI 0.57–0.66). Our separate
analyses confirmed these results: ASTRAL AUROC 0.79 (95% CI 0.78–0.80 and SPI2 AUROC
0.60 (95% CI 0.59–0.61). On formal comparative testing, there was a significant difference in
modified Rankin Scale AUROC between ASTRAL and all other scales. Sensitivity analysis iden-
tified no evidence of systematic bias from missing data.
Conclusions: Our comparative analyses confirm differences in the prognostic accuracy of stroke
scales. However, even the best performing scale had prognostic accuracy that may not be suffi-
cient as a basis for clinical decision-making. Neurology® 2017;89:997–1002
GLOSSARY
ASTRAL 5 Acute Stroke Registry and Analysis of Lausanne; AUROC 5 area under the receiver operating characteristic
curve; BI 5 Barthel Index; iSCORE-r 5 revised iSCORE; mRS 5 modified Rankin Scale score; NIHSS 5 NIH Stroke Scale;
OCSP 5 Oxfordshire Community Stroke Project; PLAN 5 preadmission comorbidities, level of consciousness, age, and
neurologic deficit; ROC5 receiver operating characteristic; SOAR5 stroke subtype, Oxfordshire Community Stroke Project,
age, and prestroke modified Rankin Scale; SOARm 5 modified stroke subtype, Oxfordshire Community Stroke Project, age,
and prestroke modified Rankin Scale; SPI2 5 Stroke Prognosis Instrument 2; THRIVE 5 Totaled Health Risks in Vascular
Events; VISTA 5 Virtual International Stroke Trials Archive.
Various tools exist to assist clinicians to quantify risk of good or poor outcome. For example, the
ABCD2 score uses clinical features to predict risk of stroke following TIA.1 Although there are
criticisms of ABCD2, it is widely used and included in stroke guidelines.2 Numerous scales
purport to predict acute stroke outcomes from baseline features.3–5 In general, these prognosis
scales have had limited traction and have not been incorporated into routine clinical practice or
guidelines.3
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There are various plausible reasons why
these scales have not been adopted by the
stroke community. Scales may be perceived
as too complex to use or may require informa-
tion that is not routinely available in the acute
setting (for example, sophisticated neuroimag-
ing).3 Often these scales report mortality;
however, given the disabling nature of stroke,
scales predicting longer-term disability may be
more useful.6
Before adopting a scale for clinical use,
clinicians and policy makers will want to see
robust evidence of external validity, i.e., evi-
dence that the scale performs well in cohorts
independent of the population used to derive
the scale. Attempts to validate scales are
emerging but such data remain lacking for
many stroke prognosis scales.3,5 Where more
than one scale is available, clinicians will want
to compare and contrast the properties of the
various scales in a common dataset. Again,
such analyses are infrequent and we have to
rely on indirect comparison across heteroge-
neous studies.
We aimed to validate and compare the
accuracy of stroke prognosis scales for predict-
ing death and disability in an independent da-
taset using patient-level data.
Figure 1 Patient flow diagram
Flow diagram shows numbers and percentage of patients with each outcome (dashed boxes) and number and percentage of patients used in each analysis
(complete boxes). ASTRAL 5 Acute Stroke Registry and Analysis of Lausanne; BI 5 Barthel Index; iSCORE-r 5 revised iSCORE; mRS 5 modified Rankin
Scale score; PLAN 5 preadmission comorbidities, level of consciousness, age, and neurologic deficit; SOAR 5 stroke subtype, Oxfordshire Community
Stroke Project, age, and prestroke modified Rankin Scale; SOARm 5 modified stroke subtype, Oxfordshire Community Stroke Project, age, and prestroke
modified Rankin Scale; SPI2 5 Stroke Prognosis Instrument 2; THRIVE 5 Totaled Health Risks in Vascular Events.
Table 1 Baseline characteristics of the Virtual International Stroke Trials
Archive (VISTA) dataset
Characteristic Overall Simultaneous analyses
Age, y 69.5 6 12.5 70.9 6 12.1
Sex, male (%) 5,909 (54.8) 327 (52.2)
Baseline NIHSS 13.4 6 5.6 14.72 6 4.3
Time to rtPA, min 65.1 6 9.1 80.62 6 82.9
Baseline glucose, mmol/L 7.6 6 3.1 7.5 6 2.6
Prestroke mRS
0 or 1 9,131 (84.7) 623 (99.5)
2 to 5 6 (0.0) 3 (0.5)
Not recorded 1,640 (15.2)
Stroke type
Hemorrhagic 571 (5.3) 626 (100.0)
Ischemic 4,621 (42.9) 0 (0.0)
Not recorded 5,585 (51.8)
OCSP
TACS 5,049 (46.8) 379 (60.5)
PACS 3,458 (32.1) 235 (37.5)
LACS 1,699 (15.8) 8 (1.3)
POCS 571 (5.3) 4 (0.6)
Abbreviations: mRS 5 modified Rankin Scale score; NIHSS 5 NIH Stroke Scale; OCSP 5
Oxfordshire Community Stroke Project; rtPA 5 recombinant tissue plasminogen activator.
Baseline characteristics of the included VISTA data given as mean 6 SD or number (%). For
reference, in the complete VISTA acute dataset mean age is 71; proportion male is 54.9%;
median baseline NIHSS is 11. LACS 5 lacunar anterior circulation syndrome; PACS 5
partial anterior circulation syndrome; POCS 5 posterior circulation syndrome; TACS 5 total
anterior circulation syndrome.
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METHODS Data sources. We used the acute section of the
Virtual International Stroke Trials Archive (VISTA; vista.gla.ac.
uk). VISTA is a not-for-profit, anonymized data repository
containing individual patient-level data from completed stroke
trials. All included trials were performed under appropriate
institutional review board and regulatory approvals, and only fully
anonymized data are held by VISTA.7
Choice of prognostic scales. We selected multi-item scales
(more than 2 items) based on focused literature review. The
search was not a systematic review; we identified scales according
to the following criteria: intended for use in acute stroke; com-
prises baseline clinical (not neuroimaging) and demographic data;
predicts outcome at 30 days (or more) poststroke; published since
2000; published in a leading topic specific journal (table e-1 at
Neurology.org).
From the chosen scales, we created a list of variables needed to
derive each and requested these data from VISTA. VISTA data
are anonymized and it is a condition of use that shared VISTA
data are not mapped back to identify the source trial. To ensure
our VISTA dataset was truly independent of the datasets used to
originally derive the scores, we collated the primary article
describing each of our included scales and shared these with the
VISTA data management team, who confirmed that the VISTA
data were independent (table e-2).
Outcomes. Our primary outcome was 90-day modified Rankin
Scale score (mRS). We dichotomized 90-day mRS with poor
outcome defined as mRS .2. Secondary outcomes were 90-day
all-cause mortality and 90-day Barthel Index (BI), dichotomized
with poor outcome defined as BI #85.
Data management. We worked with the dataset to maximize
available data. Where mortality data were not directly described,
we calculated 90-day mortality from day of death or 90-day mRS
(taking mRS 6 as death). Where Oxford stroke classification was
not available, we derived this based on NIH Stroke Scale
(NIHSS) using a validated algorithm.8 Where Canadian Neuro-
logical Scale score data were not reported, we calculated this from
NIHSS data. Certain scales included specific clinical features and
we derived the presence of these (visual field defects, loss of
consciousness, limb paresis, neglect, and aphasia) from NIHSS.
Where scales used comorbid disease, we interrogated data on
comorbidity for conditions of relevance using both categorized
and free text searches.
Statistical analyses. Our primary analyses of interest were based
around the discriminative ability of the scales. We generated
receiver operating characteristic (ROC) curves for each scale.
We calculated the area under the receiver operating characteristic
curves (AUROC) with 95% confidence intervals. We created 2
sets of ROC curves. The first included analysis of all scales for
those patients who had sufficient data, i.e., we only included pa-
tients who had data sufficient to derive a score for all of our cho-
sen scales (simultaneous analyses). For the second analysis, each
scale was assessed individually using as many patients as possible
(separate analyses). The simultaneous analysis was designed to
facilitate valid comparisons; the separate analysis was designed
to give a precise assessment of prognostic accuracy using a dataset
independent from the derivation dataset.
In addition to ROC analyses, we described individual values
for sensitivity and specificity limiting to values corresponding to
point of optimal performance on ROC curve for our primary out-
come of 90-day mRS. To describe calibration, we performed
Hosmer-Lemeshow tests of each scale’s performance against pri-
mary and secondary outcomes.
Certain variables of interest had missing data at the individual
patient level. We performed sensitivity analyses to explore the
effect of missing data by replacing missing data with extreme high
and low values for each scale.
We performed all discrimination and calibration analyses
using SPSS version 22.0 (IBM Corporation, Armonk, NY).
We formally tested the difference in AUROC between scales,
accounting for multiplicity of analyses9 (MedCalc version 16.0,
MedCalc Software, Ostend, Belgium), comparing the 6 scales
with the highest AUROC using the results of our simultaneous
and separate analyses.
RESULTS Patients. We had access to individual
patient-level data for 10,789 patients. Twelve pa-
tients were excluded as they lacked any relevant data.
Figure 1 describes included patients and their out-
comes. Table 1 contains baseline characteristics of
included patients. We derived Oxfordshire Com-
munity Stroke Project (OCSP) data for 7,533
(69.9%) patients based on their baseline NIHSS data.
All Canadian Neurological Scale scores were derived
from baseline NIHSS.
Figure 2 Receiver operating characteristic (ROC) curves generated for
modified Rankin Scale (mRS) (simultaneous analysis)
ROC curve generated for 90-day mRS .2. ASTRAL 5 Acute Stroke Registry and Analysis of
Lausanne; iSCORE-r 5 revised iSCORE; PLAN 5 preadmission comorbidities, level of con-
sciousness, age, and neurologic deficit; SOAR 5 stroke subtype, Oxfordshire Community
Stroke Project, age, and prestroke modified Rankin Scale; SOARm5 modified stroke subtype,
Oxfordshire Community Stroke Project, age, and prestroke modified Rankin Scale; SPI2 5
Stroke Prognosis Instrument 2; THRIVE 5 Totaled Health Risks in Vascular Events.
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Included scales.We assessed 8 prognostic scales: Acute
Stroke Registry and Analysis of Lausanne (ASTRAL);
iSCORE; iSCORE-r (a revised iSCORE); pre-
admission comorbidities, level of consciousness, age,
and neurologic deficit (PLAN); stroke subtype,
OCSP, age, and prestroke mRS (SOAR); SOARm (a
modified SOAR); SPI2 (Stroke Prognosis Instrument
2); and THRIVE (Totaled Health Risks in Vascular
Events).10–17
Validation. For our primary outcome, prediction of
90-day mRS, ASTRAL had the largest and SPI2 the
smallest AUROC in all analyses (figures 2 and 3).
This pattern of results was similar in our separate
analyses (table 2). Sensitivity analysis where missing
data were imputed with a best and worst case scenario
for 90-day mRS (i.e., mRS 0 and mRS 6) yielded
differing AUROC for 2 of our included scales
(iSCORE-r and SOARm). In each case, the AUROC
was less than in the original analysis (table e-3).
For prediction of 90-day mortality, ASTRAL had
the largest and SPI2 the smallest AUROC in both
analyses (figure e-1). Sensitivity analysis yielded
differing AUROC for 2 scales (iSCORE-r and
SOARm). In each case, the AUROC was less than
in the original analyses (tables e-4 and e-5).
For prediction of 90-day BI, ASTRAL had the larg-
est and SPI2 the smallest AUROC in both analyses
(figure e-2). Sensitivity analysis for 90-day BI yielded
differing AUROC for 4 scales (both iSCORE and both
SOAR variants). In each case, the AUROC was less
than in the original analyses (tables e-6 and e-7).
On formal significance tested, we observed differen-
ces in the AUROC of included scales (table e-8).
ASTRAL had significantly higher AUROC than all
other scales for 90-day mRS,2 and significantly high-
er AUROC for BI than most other scales. Differing
tests had differing patterns of sensitivity vs specificity at
point of optimal performance (table e-9).
Our analysis of calibration suggested that all scales
other than THRIVE had good calibration for 90-day
mRS. Scales of iSCORE, iSCORE-r, PLAN, and
SPI2 demonstrated good calibration for each of our
chosen outcomes (table e-10).
DISCUSSION Validation and quantitative compari-
son can assist in choice of prognostic scale, yet there
have been few articles offering such analyses in
stroke.3–5 We provide these data for recognized acute
stroke prognostic scales, with ASTRAL showing
superior prognostic utility and SPI2 the lowest prog-
nostic accuracy.
Our data highlight the value of independent,
external validation of prognostic scales. The original
ASTRAL study reported an AUROC of 0.85, with
subsequent AUROC of 0.90 in a validation study
by the ASTRAL team.10 Our data suggest a lower
prognostic accuracy (AUROC 0.82 and 0.81);
indeed, most of our analyses gave prognostic values
that are less than described in the original derivation
articles. This pattern of independent analyses report-
ing less favorable scale properties has been described
in other settings.18 Although best practice statements
for prognostic research highlight the importance of
external validation, it remains true that most progno-
sis research focuses on model development with rela-
tively limited further validation.18 We have also
shown the value of comparative analyses using a com-
mon dataset. Indirect comparisons using results from
derivation studies may have given the erroneous
impression that all scales perform equally well, poten-
tially because of differences in the sampling frames in
the original studies. Our formal testing suggests that
scales have differing discriminative properties.
Strengths of our approach include access to a large
dataset of trial quality data from a variety of sources.
We explored the possibility of missing data introduc-
ing bias through our sensitivity analyses. We offer
both comparative and individual scale level analyses
Figure 3 Receiver operating characteristic (ROC) curves generated for
modified Rankin Scale (mRS) (separate analyses)
ROC curve generated for 90-day mRS .2. ASTRAL 5 Acute Stroke Registry and Analysis of
Lausanne; iSCORE-r 5 revised iSCORE; PLAN 5 preadmission comorbidities, level of con-
sciousness, age, and neurologic deficit; SOAR 5 stroke subtype, Oxfordshire Community
Stroke Project, age, and prestroke modified Rankin Scale; SOARm5 modified stroke subtype,
Oxfordshire Community Stroke Project, age, and prestroke modified Rankin Scale; SPI2 5
Stroke Prognosis Instrument 2; THRIVE 5 Totaled Health Risks in Vascular Events.
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and describe ROC and individual sensitivity, specific-
ity, and calibration values. We hope these data will
help clinicians choose whether to use a prognosis scale
and which is most appropriate.
There were limitations to our analyses. We maxi-
mized data available for analyses by deriving certain
input variables; we recognize this may introduce bias.
To facilitate analyses, we dichotomized mRS and BI
data. Our selected thresholds were in keeping with
those commonly used in trials and prognostic work.19
However, we appreciate that this approach fails to
capture the range of functional outcomes that can
follow stroke. We limited our analysis to those
multi-item scales, described in selected journals that
use variables potentially available in VISTA. Thus, we
not have included certain prognostic scales.5,20 A
comprehensive, systematic review could be a future
direction for this work. For any analysis that uses trial
data there is always a concern regarding generalizabil-
ity to a real-world population. Patients included in
our analysis were younger and less impaired than may
be seen in an unselected cohort. We would encourage
similar analyses using large-scale observational cohort
data.
Our data would support the use of the ASTRAL
scale, as this scale had the greatest predictive accuracy
and already has published external validation studies.
However, choice of prognostic scale, or indeed the
decision to use these scales at all, is dependent on
many factors in addition to prognostic accuracy. Ease
of use at the bedside is an important consideration,
particularly in the hyperacute stroke setting. The scale
with the fewest included variables was SOAR and this
showed moderate predictive accuracy.
We deliberately chose not to have a threshold
value that signified “acceptable” accuracy. The value
of a prognostic or diagnostic instrument is relative to
the context of the assessment and absolute values are
unhelpful in determining the utility of a scale in prac-
tice.18,21 Scales can serve an assistive or decisive func-
tion.22,23 The appropriateness of basing clinical
decisions solely or partly on prognostic scales is a fac-
tor of both the accuracy of the scale and the cost of
a misclassification. In the acute setting, if the scales
are being used to inform decisions regarding life-
saving treatment, it is debatable whether accuracy
values perceived as statistically acceptable are also
clinically acceptable. For example, with a specificity
of around 0.8, 1 in 5 may be wrongly assigned a poor
prognosis and treated accordingly.
Potential solutions to improving scale properties
include adding the most discriminating factors from
other scales to create a new scale or using scales in
series. Our analysis of individual sensitivity and spec-
ificity scores suggest that some scales favor sensitivity
and vice versa. Thus there may be utility in using, for
example, a highly sensitive scale followed by a highly
specific scale. Such approaches may have value, but
will add complexity to assessment and ultimately
would represent new scales that require further valida-
tion. It may also be useful for future research to focus
on a better understanding of the characteristics of
Table 2 Area under receiver operating characteristic curve (AUROC) for primary analysis (modified Rankin
Scale [mRS])
Separate analyses Simultaneous analysis Derivation study
AUROC (95% CI) No. (%) AUROC (95% CI) No. (%) AUROC (95% CI)
ASTRAL 0.79 (0.78–0.80) 5344 (49.6) 0.78 (0.75–0.82) 627 (5.8) 0.85
iSCORE 0.68 (0.67–0.70) 5551 (51.5) 0.66 (0.61–0.70) 0.82 (0.81–0.83)
iSCORE-r 0.77 (0.76–0.78) 5551 (51.5) 0.74 (0.70–0.78) 0.80
PLAN 0.76 (0.75–0.77) 5549 (51.5) 0.74 (0.70–0.78) 0.84 (0.82–0.85)a
SOAR 0.68 (0.66–0.70) 4051 (37.6) 0.66 (0.62–0.71) 0.82 (0.79–0.84)b
SOARm 0.75 (0.73–0.76) 4051 (37.6) 0.70 (0.66–0.74) 0.83 (0.79–0.86)c
SPI2 0.60 (0.59–0.61) 10033 (93.1) 0.61 (0.57–0.66) 0.63 (0.62–0.65)d
THRIVE 0.77 (0.76–0.78) 10033 (93.1) 0.73 (0.69–0.77) 0.71
Abbreviations: ASTRAL 5 Acute Stroke Registry and Analysis of Lausanne; CI 5 confidence interval; iSCORE-r 5 revised
iSCORE; PLAN 5 preadmission comorbidities, level of consciousness, age, and neurologic deficit; SOAR 5 stroke subtype,
Oxfordshire Community Stroke Project, age, and prestroke modified Rankin Scale; SOARm 5 modified stroke subtype,
Oxfordshire Community Stroke Project, age, and prestroke modified Rankin Scale; SPI2 5 Stroke Prognosis Instrument 2;
THRIVE 5 Totaled Health Risks in Vascular Events.
AUROC (95% CI) and n (%) of patients in our analyses for 90-day mRS .2.
aPrimary outcomes for derivation studies: 1-year mortality.
b Primary outcomes for derivation studies: 7-day mortality.
c Primary outcomes for derivation studies: discharge mortality.
d Primary outcomes for derivation studies: stroke or death within 2 years.
International Stroke Trials Archive.
Neurology 89 September 5, 2017 1001
ª 2017 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
those patients who are most likely to be misclassified
by scales. Our work highlights recommendations by
groups such as MRC PROGRESS18 that develop-
ment of future scales include comparison against pre-
existing scales and inclusion of systems to allow for
independent, external validation of the scale.
There are many scales designed to provide prog-
nostic information following acute stroke. Our com-
parative analyses suggest that certain scales (e.g.,
ASTRAL) may have better prognostic accuracy than
others, although this accuracy was substantially lower
than described in the original derivation articles.
Based on our data, even the scales with the best prop-
erties may not have sufficient prognostic power to be
used as the sole basis for important treatment
decisions.
AUTHOR CONTRIBUTIONS
Terence J. Quinn: study concept and design, interpretation of data,
acquisition of data, study supervision, critical review of manuscript. Sarjit
Singh: data management, analysis and interpretation of data, drafting
manuscript. Kennedy R. Lees and Philip M. Bath: input to methods
and analyses, critical review of manuscripts. Phyo K. Myint: study con-
cept and design, study supervision, critical review of manuscript.
ACKNOWLEDGMENT
The authors thank Myzoon Ali (University of Glasgow) for assistance with
obtaining dataset access.
STUDY FUNDING
No targeted funding reported.
DISCLOSURE
The authors report no disclosures relevant to the manuscript. Go to
Neurology.org for full disclosures.
Received January 25, 2017. Accepted in final form June 15, 2017.
REFERENCES
1. Johnston KC, Wagner DP, Wang XQ, et al. Validation of
an acute ischemic stroke model: does diffusion-weighted
imaging lesion volume offer a clinically significant
improvement in prediction of outcome? Stroke 2007;38:
1820–1825.
2. National Institute for Health and Clinical Excellence
(NICE). Stroke and Transient Ischaemic Attack in Over
16s : Diagnosis and Initial Management [online]. Nice
Guideline. 2008. Available at: nice.org.uk/guidance/CG68.
Accessed May 3, 2017.
3. Counsell C, Dennis M. Systematic review of prognostic
models in patients with acute stroke. Cerebrovasc Dis
2001;12:159–170.
4. Mattishent K, Kwok CS, Mahtani A, Pelpola K, Myint
PK, Loke YK. Prognostic indices for early mortality in
ischaemic stroke: meta-analysis. Acta Neurol Scand
2016;133:41–48.
5. Teale EA, Forster A, Munyombwe T, Young JB. A sys-
tematic review of case-mix adjustment models for stroke.
Clin Rehabil 2012;26:771–786.
6. Solomon NA, Glick HA, Russo CJ, Lee J, Schulman KA.
Patient preferences for stroke outcomes. Stroke 1994;25:
1721–1725.
7. Ali M, Bath PMW, Curram J, et al. The virtual interna-
tional stroke trials archive. Stroke 2007;38:1905–1910.
8. Ali M. The Virtual International Stroke Trials Archive
(VISTA): Promulgation of a Clinical Trial Resource [online].
University of Glasgow; 2008. Available at: theses.gla.ac.uk/
509/1/2008AliPhD_.pdf. Accessed May 3, 2017.
9. DeLong ER, DeLong DM, Clarke-Pearson DL. Compar-
ing the areas under two or more correlated receiver oper-
ating characteristic curves: a nonparametric approach.
Biometrics 1988;44:837–845.
10. Ntaios G, Faouzi M, Ferrari J, Lang W, Vemmos K,
Michel P. An integer-based score to predict functional
outcome in acute ischemic stroke: the ASTRAL score.
Neurology 2012;78:1916–1922.
11. Saposnik G, Fang J, Kapral MK, et al. The iScore predicts
effectiveness of thrombolytic therapy for acute ischemic
stroke. Stroke 2012;43:1315–1322.
12. Sung SF, Chen YW, Hung LC, Lin HJ. Revised iScore to
predict outcomes after acute ischemic stroke. J Stroke Cer-
ebrovasc Dis 2014;23:1634–1639.
13. O’Donnell MJ, Fang J, D’Uva C, et al. The PLAN score:
a bedside prediction rule for death and severe disability
following acute ischemic stroke. Arch Intern Med 2012;
172:1548–1556.
14. Kwok CS, Potter JF, Dalton G, et al. The SOAR stroke
score predicts inpatient and 7-day mortality in acute
stroke. Stroke 2013;44:2010–2012.
15. Abdul-Rahim AH, Quinn TJ, Alder S, et al. Derivation
and validation of a novel prognostic scale (modified-stroke
subtype, Oxfordshire Community Stroke Project classifi-
cation, age, and prestroke modified Rankin) to predict
early mortality in acute stroke. Stroke 2016;47:74–79.
16. Kernan WN, Viscoli CM, Brass LM, et al. The Stroke
Prognosis Instrument II (SPI-II): a clinical prediction
instrument for patients with transient ischemia and non-
disabling ischemic stroke. Stroke 2000;31:456–462.
17. Flint AC, Faigeles BS, Cullen SP, et al. THRIVE score
predicts ischemic stroke outcomes and thrombolytic hem-
orrhage risk in VISTA. Stroke 2013;44:3365–3369.
18. Steyerberg E, Moons KGM, van der Windt D, et al. Prog-
nosis research strategy (PROGRESS) series 3: prognostic
models. Br Med J 2012;10:e1001381.
19. Quinn TJ, Dawson J, Walters MR, Lees KR. Functional
outcome measures in contemporary stroke trials. Int J
Stroke 2009;4:200–205.
20. Saposnik G, Guzik AK, Reeves M, Ovbiagele B, Johnston
SC. Stroke prognostication using age and NIH Stroke
Scale: SPAN-100. Neurology 2013;80:21–28.
21. Noel-Storr AH, McCleery JM, Richard E, et al. Report-
ing standards for studies of diagnostic test accuracy in
dementia: the STARDdem Initiative. Neurology 2014;
83:364–373.
22. Liao L, Mark DB. Clinical prediction models: are we
building better mousetraps? J Am Coll Cardiol 2003;42:
851–853.
23. Laupacis A, Sekar NClinical prediction rules. JAMA 1997;
277:488–494.
1002 Neurology 89 September 5, 2017
ª 2017 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
